iLIVER最新文献

{"title":"Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic hepatitis B","authors":"Wen-Xin Wang ,&nbsp;Xiaoyan Li ,&nbsp;Xue-Yuan Jin ,&nbsp;Rui Jia ,&nbsp;Hong-Min Wang ,&nbsp;Shuang-Nan Zhou ,&nbsp;Xin Zhang ,&nbsp;Ying-Ying Gao ,&nbsp;Fu-Sheng Wang ,&nbsp;Junliang Fu","doi":"10.1016/j.iliver.2024.100107","DOIUrl":"10.1016/j.iliver.2024.100107","url":null,"abstract":"<div><h3>Background and aims</h3><p>To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B (CHB) patients previously treated with nucleot(s)ide analogs (NAs) followed by combined treatment with an NA and pegylated interferon alpha (PEG-IFNα).</p></div><div><h3>Methods</h3><p>Ninety-nine patients with serum levels of HBsAg &lt;3000 IU/mL and HBV DNA &lt;20 IU/mL who received prior NA treatment were enrolled. Participants were administered either NA monotherapy (NA group) or combination therapy with PEG-IFNα (Add-on group). Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12- and 24-week intervals. The outcome of this study was a loss or &gt;1 log₁₀ IU/mL decline in serum HBsAg.</p></div><div><h3>Results</h3><p>After 48 weeks of antiviral therapy, none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss. Baseline serum HBsAg and IP-10 levels were equivalent across both groups. The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels. Furthermore, a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group. Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group (<em>p</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNα among patients with CHB treated with NAs.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100107"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782400032X/pdfft?md5=05062282b65b7d860c2f3674209bd868&pid=1-s2.0-S277294782400032X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities","authors":"Gong Feng ,&nbsp;Ya-Fei Fan ,&nbsp;Ru-Xin Li ,&nbsp;Giovanni Targher ,&nbsp;Christopher D. Byrne ,&nbsp;Ming-Hua Zheng","doi":"10.1016/j.iliver.2024.100113","DOIUrl":"10.1016/j.iliver.2024.100113","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000380/pdfft?md5=900c268f6fb3052db25147560b9aa2ec&pid=1-s2.0-S2772947824000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic research on MASLD: New insights into cardiovascular disease and cancer risk","authors":"Ming Yang,&nbsp;Juan Liu","doi":"10.1016/j.iliver.2024.100108","DOIUrl":"10.1016/j.iliver.2024.100108","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000331/pdfft?md5=45e308ef2f4897a9eff0d22fcfb13eeb&pid=1-s2.0-S2772947824000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimising postoperative surveillance for hepatocellular carcinoma: Beyond histological predictors","authors":"Jiahao Xu ,&nbsp;Lihui Gu ,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100110","DOIUrl":"10.1016/j.iliver.2024.100110","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000355/pdfft?md5=08e6e95a553cdb667d6ca485e4835264&pid=1-s2.0-S2772947824000355-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCL16 inhibits tumor proliferation and metastasis in HCC by impacting CK19 phenotype","authors":"Huigang Li ,&nbsp;Jianyong Zhuo ,&nbsp;Peiru Zhang ,&nbsp;Jinyan Chen ,&nbsp;Zuyuan Lin ,&nbsp;Xudong Yang ,&nbsp;Ruijie Zhao ,&nbsp;Chenghao Cao ,&nbsp;Wei Shen ,&nbsp;Chiyu He ,&nbsp;Hao Chen ,&nbsp;Ting Lv ,&nbsp;Xuyong Wei ,&nbsp;Shusen Zheng ,&nbsp;Xiao Xu ,&nbsp;Di Lu","doi":"10.1016/j.iliver.2024.100096","DOIUrl":"10.1016/j.iliver.2024.100096","url":null,"abstract":"<div><h3>Background and aims</h3><p>Cytokeratin 19–positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype with poor outcomes. The initiation and development of CK19+ HCC in the background of liver cirrhosis remains unclear. This study investigated the role of the cirrhosis-related gene C–C motif chemokine ligand 16 (CCL16) in the development of CK19+ HCC.</p></div><div><h3>Methods</h3><p>Datasets from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were analyzed to screen and validate the genes associated with CK19+ HCC. A total of 102 HCC patients were included for tissue microarray analysis. Gain-of-function experiments were conducted to investigate the biological functions of CCL16. CIBERSORT was used to investigate the correlation of CCL16 and immune infiltration.</p></div><div><h3>Results</h3><p>GEO dataset analysis showed that CK19+ HCC had lower expression of CCL16. In both TCGA dataset and our HCC cohort, CCL16 expression was negatively correlated with CK19 expression (<em>P</em> ​&lt; ​0.05) and its expression was higher in para-tumor than tumor tissues (<em>P</em> ​&lt; ​0.001). Moreover, low CCL16 expression was related to advanced stage and poor overall survival (<em>P</em> ​&lt; ​0.05). CCL16 overexpression downregulated CK19 expression and impacted the sphere formation ability of HCC cells. Overexpression of CCL16 inhibited the cell proliferation, migration, and invasion of HCC cell lines. Immune analysis showed HCC with high CCL16 expression had more infiltration of mast cells. HCC patients with both low CCL16 expression and low mast cells had the worst prognosis (<em>P</em> ​&lt; ​0.001).</p></div><div><h3>Conclusion</h3><p>Our data indicated that CCL16 downregulated the expression of CK19 and inhibited the malignant phenotype of HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100096"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000215/pdfft?md5=b5bdf50abc10a7dd4931f45f1e281ee8&pid=1-s2.0-S2772947824000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141133699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Setting up an integrated service for PSC-IBD patients: A quality improvement project","authors":"Sreelakshmi Kotha,&nbsp;Ioannis Koumoutsos,&nbsp;Ben Warner,&nbsp;Eleni Theocharidou,&nbsp;Joel Mawdsley,&nbsp;Philip Berry","doi":"10.1016/j.iliver.2024.100076","DOIUrl":"10.1016/j.iliver.2024.100076","url":null,"abstract":"<div><h3>Background and aims</h3><p>Primary sclerosing cholangitis (PSC) often co-exists with inflammatory bowel disease (IBD) and together they are associated with increased risk of complications, including cancer (hepatobiliary, colorectal, gallbladder) and death. Guidelines for follow up and surveillance vary, but our local guidelines advise annual surveillance with magnetic resonance cholangiopancreatography (MRCP), colonoscopy and ultrasound (US) (6 monthly if cirrhotic). We aimed to assess the quality of care in our PSC-IBD patients, including adherence to local surveillance guidelines, and resultant detection of complications, before and after the introduction of an integrated PSC and IBD out-patient service.</p></div><div><h3>Methods</h3><p>Data on management of PSC-IBD patients was collected retrospectively before, and prospectively following, the introduction of an integrated service. Descriptive comparisons of diagnoses, adherence to planned surveillance and outcomes were made between cohorts pre- and post-service redesign.</p></div><div><h3>Results</h3><p>Prior to the service re-design there was significant variability in care and poor adherence to guidelines. Introduction of an integrated PSC-IBD service led to 89 referrals with possible PSC-IBD at 36 months after service re-design. Detailed review led to appropriate identification of 68 PSC-IBD patients. There was significant improvement in surveillance with annual colonoscopy in 90%, MRI/MRCP in 81%, US in 35%, compared to 55%, 55% and 7% respectively in the baseline cohort. This translated to diagnosis and appropriate treatment of colonic dysplasia in 4 patients, colorectal cancer (CRC) in 4 patients and cholangiocarcinoma (CCA) in 2 patients.</p></div><div><h3>Conclusion</h3><p>Establishment of an integrated out-patient service for PSC-IBD patients results in better compliance with guidelines, effective detection of complications, and appropriate management.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100076"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782400001X/pdfft?md5=35c1c6c9dd0795abd3cb099d97232389&pid=1-s2.0-S277294782400001X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139831646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome is associated with significant hepatic fibrosis and steatosis in patients with nonalcoholic steatohepatitis","authors":"Qian-Qian Li ,&nbsp;Yu-Ting Xiong ,&nbsp;Danni Wang ,&nbsp;Ke-Xin Wang ,&nbsp;Chang Guo ,&nbsp;Yi-Ming Fu ,&nbsp;Xiao-Xia Niu ,&nbsp;Chun-Yan Wang ,&nbsp;Jian-Jun Wang ,&nbsp;Dong Ji ,&nbsp;Zhi-Fang Bai","doi":"10.1016/j.iliver.2024.100094","DOIUrl":"10.1016/j.iliver.2024.100094","url":null,"abstract":"<div><h3>Background and aims</h3><p>Nonalcoholic steatohepatitis (NASH), an inflammatory form of non-alcoholic fatty liver disease, can progress to advanced liver fibrosis, cirrhosis, and liver cancer. Metabolic syndrome (MetS) parallels the prevalence of non-alcoholic fatty liver disease/NASH and increases patients’ risk of advanced liver disease. This study aimed to determine whether MetS was associated with the histological progression of NASH.</p></div><div><h3>Methods</h3><p>Patients with liver biopsy-proven NASH were retrospectively screened and categorized into two groups for each histological feature: with (&lt;2 points) or without (≥2 points) significant hepatic steatosis/inflammation/fibrosis. Multivariable logistic regression was used to explore the association between MetS and histological features.</p></div><div><h3>Results</h3><p>In total, 386 patients with a median age of 33.0 years were enrolled; among them, 35.2% were female, and 41.2% had MetS. The proportion of significant hepatic fibrosis and steatosis in those with MetS was significantly higher than in those without MetS (<em>p</em> &lt; 0.05). Multivariable logistic regression analyses showed that MetS remained significantly associated with significant hepatic fibrosis (adjusted odds ratio: 1.852, 95% confidence interval: 1.042–3.292, <em>p</em> = 0.036), and severe hepatic steatosis (adjusted odds ratio: 2.008, 95% confidence interval: 1.030–3.914, <em>p</em> = 0.041).</p></div><div><h3>Conclusion</h3><p>MetS was associated with significant hepatic fibrosis and steatosis in patients with NASH. Our results suggest that NASH patients with MetS should be closely monitored and given targeted intervention and treatment, which may help to prevent disease progression and mitigate the growing burden of NASH.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000197/pdfft?md5=ea4ea081a890891e2b017963d6e2344a&pid=1-s2.0-S2772947824000197-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140768689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of cessation of nucleoside/nucleotide analogues in Chinese patients with HBeAg-negative chronic hepatitis B","authors":"Fengyi Li ,&nbsp;Yadong Zhang ,&nbsp;Chao Liu ,&nbsp;Juan Li ,&nbsp;Dali Zhang ,&nbsp;Yinjie Gao","doi":"10.1016/j.iliver.2024.100093","DOIUrl":"10.1016/j.iliver.2024.100093","url":null,"abstract":"<div><h3>Background</h3><p>Cessation of nucleoside/nucleotide analogue (Nuc) therapy in patients with HBeAg-negative chronic hepatitis B (CHB) remains controversial.</p></div><div><h3>Methods</h3><p>In this prospective, single-center cohort study, we recruited 45 patients with HBeAg-negative CHB from The Fifth Medical Center of Chinese People's Liberation Army General Hospital in mainland China. Patients were classified into a Nuc cessation group (<em>n</em> = 27) and Nuc continuation group (<em>n</em> = 18) and followed-up for 36 months. Nuc were stopped after being inactive for at least 4 years (normal alanine aminotransferase (ALT), undetectable hepatitis B virus (HBV) DNA), with liver fibrosis ≤ Stage1 (S1) and inflammation ≤ Grade (G1).</p></div><div><h3>Results</h3><p>Within 3 years of follow-up, 51.9% patients with Nuc cessation had virological relapse and 14.8% had ALT elevation, while all patients with Nuc continuation had undetectable HBV DNA and normal ALT. The rate of HBsAg loss after Nuc cessation was 22.2% compared with no seroconversion in patients with Nuc continuation. The hepatitis flare rate was 11.1% and there were no cases of hepatic decompensation after Nuc cessation. End of treatment (EOT) HBsAg, HBV RNA, and decline in HBV core-related antigen (HBcrAg) rate were predictive markers for HBsAg seroconversion at 6 months post-Nuc cessation.</p></div><div><h3>Conclusions</h3><p>This study showed favorable HBsAg loss and low hepatitis flare rates after Nuc cessation. EOT HBsAg, HBV RNA, and decline in HBcrAg rate were predictive markers for HBsAg seroconversion at 6 months post-Nuc cessation.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100093"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000185/pdfft?md5=281d1e196ead862d400d47395ba25156&pid=1-s2.0-S2772947824000185-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140398463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury","authors":"Yu-Ting Xiong ,&nbsp;Jian-Fei Wang ,&nbsp;Le Li ,&nbsp;Zhi-Fang Bai ,&nbsp;Yan Liu ,&nbsp;Ang Huang ,&nbsp;Ke-Xin Wang ,&nbsp;Yiming Fu ,&nbsp;Wucai Yang ,&nbsp;Chang Guo ,&nbsp;Mengwen He ,&nbsp;Wen-Chang Wang ,&nbsp;Chun-Yan Wang ,&nbsp;Dong Ji","doi":"10.1016/j.iliver.2024.100095","DOIUrl":"10.1016/j.iliver.2024.100095","url":null,"abstract":"<div><h3>Background</h3><p>Currently, research on biopsy-proven acute drug-induced liver injury (DILI) remains limited. This study aimed to identify clinical characteristics and risk factors for significant hepatic inflammation in patients with acute DILI.</p></div><div><h3>Methods</h3><p>An ambispective cohort study was conducted on biopsy-proven acute DILI patients admitted to our hospital from 2012 to 2018. Using the Scheuer scoring system, patients were categorized into G0-2 or G3-4 groups and followed up for 12 months after first admission. Clinical characteristics and outcomes were retrieved from medical records.</p></div><div><h3>Results</h3><p>The median age of the 157 enrolled patients (65.6% female) was 40.4 (interquartile range (IQR), 31.9–49.1) years. The median latency and length of hospitalization were 30.0 (IQR, 5.0–60.0) and 18.0 (IQR, 12.0–26.0) days. The proportions of patients in the G0-2 and G3-4 groups were 54.8% and 45.2%, respectively. Logistic regression analysis revealed that females (odds ratio (OR): 2.623, 95% confidence interval (CI): 1.169–5.887, <em>p</em> = 0.019), higher body mass index (OR: 1.168, 95% CI: 1.029–1.325, <em>p</em> = 0.016), higher total bilirubin (OR: 1.004, 95% CI: 1.000–1.007, <em>p</em> = 0.047), and lower prothrombin activity (OR: 0.976, 95% CI: 0,957–0.995, <em>p</em> = 0.013) were associated with significant hepatic inflammation. The predominance of the hepatocellular injury pattern (60.5%) at admission transformed into a predominance of the cholestatic pattern (60.5%) at discharge. During follow-up, 23 patients (14.6%) developed chronic DILI, with nine patients (5.7%) progressing to cirrhosis. Moreover, 15 female patients (9.6%) developed autoimmunity (3cases in the G0-2 group vs 12 cases in the G3-4 group, <em>p</em> &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>Acute DILI patients with high-risk factors were more likely to develop significant hepatic inflammation, and females with significant inflammation were at a higher risk of developing autoimmunity during follow-up.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100095"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000203/pdfft?md5=645003e67eda5eb4ceb14fc881bc62ed&pid=1-s2.0-S2772947824000203-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141038690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease","authors":"Wei Ouyang ,&nbsp;Ming-Da Wang ,&nbsp;Ming-Cheng Guan ,&nbsp;Yong-Kang Diao ,&nbsp;Li-Yang Sun ,&nbsp;Nan-Ya Wang ,&nbsp;Feng Shen ,&nbsp;Hong Zhu ,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100098","DOIUrl":"10.1016/j.iliver.2024.100098","url":null,"abstract":"<div><h3>Background and aims</h3><p>The ASAP and GALAD scores are widely used diagnostic models for detecting hepatocellular carcinoma (HCC), incorporating factors such as sex, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II), and lens culinaris agglutinin-reactive fraction of AFP (AFP-L3%). This study compares the diagnostic efficacy of the ASAP and GALAD scores in the early detection of HCC in patients with non-alcoholic fatty liver disease (NAFLD).</p></div><div><h3>Methods</h3><p>NAFLD patients with and without HCC were recruited from 12 Chinese tertiary hospitals. Serum levels of AFP, PIVKA-II, and AFP-L3% were measured. The diagnostic accuracy of individual biomarkers, the ASAP score, and the GALAD score in detecting NAFLD-HCC at various stages was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) values.</p></div><div><h3>Results</h3><p>In a cohort of 147 NAFLD-HCC cases and 460 NAFLD controls, both the ASAP and GALAD scores outperformed individual biomarkers in detecting NAFLD-HCC. The ASAP score demonstrated a high AUC of 0.910 (sensitivity: 80.3%, specificity: 92.8%) for identifying NAFLD-HCC at all stages, surpassing AFP (AUC: 0.716, <em>P</em> &lt; 0.001), PIVKA-II (AUC: 0.849, <em>P</em> &lt; 0.001), AFP-L3% (AUC: 0.663, <em>P</em> &lt; 0.001), and the GALAD score (AUC: 0.882, <em>P</em> = 0.014). Comparable results were observed for early-stage NAFLD-HCC and for detecting HCC in NAFLD patients with or without cirrhosis.</p></div><div><h3>Conclusion</h3><p>The ASAP score, which excludes the AFP-L3% indicator, demonstrated superior performance in differentiating NAFLD-HCC compared to the GALAD score, suggesting its potential for early screening of HCC in NAFLD patients.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100098"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000239/pdfft?md5=3f1832536c1a71cc8de9d107a8cce2c7&pid=1-s2.0-S2772947824000239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141139101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}